Bristol Myers Squibb stock: Camzyos data support pediatric case

Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM trial on November 6, 2026, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The study evaluated Camzyos (mavacamten) in patients aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy. The company described the findings as consistent with the earlier 28-week results in its Bristol Myers Squibb investor news release.

Bristol Myers Squibb stock traded at 56.39 euros on Lang & Schwarz at 12:42 CET on Monday, November 9, 2026, 0.70 percent above the Xetra close of Friday, November 6. The comparison uses the last completed Xetra session before the Monday trading day.

Trial results reinforce Camzyos positioning

SCOUT-HCM randomized 44 participants, with 43 completing the initial 28-week placebo-controlled period and moving into active treatment. Patients who received mavacamten throughout the study recorded a mean change from baseline of minus 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to Camzyos at week 28 achieved a similar reduction.

The safety profile remained consistent with earlier results, according to the company. In the continuous-treatment group, five treatment-related treatment-emergent adverse events and two serious events were reported over 56 weeks. The placebo-to-mavacamten group recorded one treatment-related event and no serious event during its 28-week active-treatment period. No patient experienced a left ventricular ejection fraction below 50 percent during the 56-week evaluation.

Bristol Myers Squibb's chief medical officer, Cristian Massacesi, said the additional results provide further confidence for healthcare providers considering treatment options for pediatric patients. The findings also extend the evidence base for Camzyos after the U.S. Food and Drug Administration approved the medicine in September 2026 for patients weighing at least 30 kilograms with symptomatic obstructive hypertrophic cardiomyopathy.

The company said further Camzyos presentations covering clinical and real-world evidence would be shared at the American Heart Association's Scientific Sessions from November 6 to 9 in Chicago. For investors, the pediatric indication adds a new patient segment to a medicine already approved for adults, while the trial's limited size means longer-term uptake and safety monitoring remain important to the commercial outlook.

Investors can follow the real-time quote of Bristol Myers Squibb stock for further market moves.

The S&P 500 provides the relevant broader market backdrop for the U.S.-listed pharmaceutical company.

More news and analyses on Bristol Myers Squibb stock cover subsequent pipeline, regulatory and financial developments.